LEAD 2

Card Set Information

Author:
Susanslcm
ID:
45577
Filename:
LEAD 2
Updated:
2010-10-27 21:47:19
Tags:
LEAD
Folders:

Description:
EFFICACY AND SAFETY COMPARISON OF LIRAGLUTIDE, GLIMEPRIDE ADN PLACEBO. ALL IN COMBINATION WITH METFORMIN IN T2 DIABETES
Show Answers:

Home > Flashcards > Print Preview

The flashcards below were created by user Susanslcm on FreezingBlue Flashcards. What would you like to do?


  1. HOW MANY WEEKS IS THE LEAD 2 STUDY?
    26 WEEKS
  2. WHAT WAS THE STUDY DESIGN FOR THE LEAD 2 STUDY?
    RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO AND AACTIVE CONTROL GROUP
  3. HOW WAS THE AUTHOR OF LEAD 2
    NAUCK
  4. WHAT WERE THE INCLUSION CRITERIA FOR LEAD 2
    • 7-11% FOR PATIENTS ON PREVIOUS OAD MONOTHERAPY >3 MONTHS
    • 7-10% for patients for previous oad combinations therapy >3 months
    • MEAN A1C 8.4%

    AGE 18-80 YEARS
  5. PRIMARY OUTCOME MEASURE FOR LEAD 2
    CHANGE IN A1C AFTER 26 WEEKS
  6. SECONDARY EFFICACY IN LEAD 2
    CHANGE IN BODY WEIGHT, FPG , BETA CELL FUNTION SBP
  7. WHAT WAS THE CHANGE IN BODY WEIGHT IN LEAD 2
    0.6 -3.96

    1.2 -5.72

    1.8 -6.16

    GLIM 4.0 +2.2
  8. PERCENTAGE OF PATIENTS THAT REACHED ADA GOAL IN LEAD 2 IN MONOTHERAPY ARM
    1.2MG 52.8

    1.8MG 66.3
  9. WHAT WERE THE MINOR HYPO RATES IN THE LEAD 2 STUDY?
    0.6MG 3.3

    1.2MG 0.8

    • 1.8MG 2.5
    • GLIM 16.9

What would you like to do?

Home > Flashcards > Print Preview